The U.S. Food and Drug Administration (FDA) has approved the long-awaited Belsomra (suvorexant) tablets for difficulty in falling and staying asleep (insomnia). Belsomra, an orexin receptor antagonist, is the first approved drug in this new class. Belsomra blocks the action of orexin, a chemical involved in the sleep-wake cycle in the brain. The FDA has approved Belsomra in 5, 10, 15, and 20 milligram (mg) strengths. Belsomra is taken within 30 minutes of bed and no more than once per night with a max daily dose of 20 mg. After taking, at least seven hours should remain for uninterrupted sleep. Belsomra is expected to be available in pharmacies in late 2014 or early 2015.
Belsomra is a sleep drug indicated for treating insomnia. This drug regulates sleep and the wake cycle. Insomnia is a disorder which causes difficulties in falling asleep or maintaining sleep. One with insomnia will show difficulties in sleeping, wakes up often especially at night, and might have troubles getting sleep. One also wakes up too early in the morning and feels tired upon waking up. Belsomra is a medication in a new class of drugs known as orexin receptor antagonists. These drugs target orexins, which are brain chemicals responsible for regulating the wake-sleep cycle in a person. Belsomra blocks the orexin receptor thus suppressing wakefulness. The orexin neuropeptide signals help in promoting wakefulness.
Belsomra (suvorexant) is a special medication that treats insomnia (a sleeping problem). The medicine helps in regulating the sleeping and waking cycle in people who are finding it hard to sleep. Belsomra is a sedative-hypnotic drug that works in the brain by producing a coming effect to allow for the normal sleeping cycle.
Insomnia is caused by the imbalances of chemicals in the brain, and this results in a distorted sleeping cycle. This is why some people will find it hard to sleep at night and stay awake all night. Belsomra should be used for a short period of 7 to 10 days and if the condition persists, seek medical assistant. The drug should be administered orally.